Company Media

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that a knack for numbers has informed his leadership style.

Immuron Ltd posted a revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.

Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.

Immuron Limited CEO Steven Lydeamore joined Steve Darling from Proactive to share news about the Australian Biotech company that is looking at using its technology for product development around gut health

Immuron (ASX:IMC) CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference on Friday 4 November 2022.

Immuron (IMC) listed as a company to watch in the recent Stockhead investor guide.

Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates.

Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22.

Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.

Immuron (IMC) is surging on the ASX today after revealing some encouraging progress in the development of a treatment for diarrhoea.

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.

Shares of Immuron Ltd. IMRN, -2.72% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary....

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.

Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.

Biopharmaceutical company Immuron (IMC) has executed its previously announced research agreement involving the US Naval Medical Research Centre and the CSIRO.

Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....

The U.S.-listed shares of Immuron Ltd.  skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested.....

Research surveys have shown that around one in four travellers changes their travel itinerary due to diarrhoea and around 5% have to seek medical attention.